首页|Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

Patient Assessment and Therapy Planning Based on Homologous Recombination Repair Deficiency

扫码查看
原文链接
  • NETL
  • NSTL
  • 万方数据
Defects in genes involved in the DNA damage response cause homologous recombination repair deficiency(HRD).HRD is found in a subgroup of cancer patients for several tumor types,and it has a clinical relevance to cancer prevention and therapies.Accumulating evidence has iden-tified HRD as a biomarker for assessing the therapeutic response of tumor cells to poly(ADP-ribose)polymerase inhibitors and platinum-based chemotherapies.Nevertheless,the biology of HRD is complex,and its applications and the benefits of different HRD biomarker assays are controversial.This is primarily due to inconsistencies in HRD assessments and definitions(gene-level tests,geno-mic scars,mutational signatures,or a combination of these methods)and difficulties in assessing the contribution of each genomic event.Therefore,we aim to review the biological rationale and clin-ical evidence of HRD as a biomarker.This review provides a blueprint for the standardization and harmonization of HRD assessments.

DNA damage responseHomologous recombination repair deficiencyPoly(ADP-ribose)polymerase inhibitorBiomarkerHarmonization

Wenbin Li、Lin Gao、Xin Yi、Shuangfeng Shi、Jie Huang、Leming Shi、Xiaoyan Zhou、Lingying Wu、Jianming Ying

展开 >

Department of Pathology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

Geneplus-Shenzhen,Shenzhen 518000,China

Institute of Microbiology,Chinese Academy of Sciences,Beijing 100101,China

Geneplus-Beijing,Beijing 102206,China

National Institutes for Food and Drug Control,Beijing 100050,China

State Key Laboratory of Genetic Engineering,Human Phenome Institute,School of Life Sciences,Fudan University,Shanghai 200438,China

Department of Pathology,Fudan University Shanghai Cancer Center,Shanghai 200032,China

Department of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing 100021,China

展开 >

National Key R&D Program of ChinaNational Natural Science Foundation of ChinaBeijing Nova Program of Science and TechnologyChinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical SciencesBeijing Hope Run Special Fund of Cancer Foundation of China

2022YFC240990282172876Z1911000011190952021-I2M-1-066LC2019L04

2023

10.1016/j.gpb.2023.02.004

基因组蛋白质组与生物信息学报(英文版)
中国科学院北京基因组研究所

基因组蛋白质组与生物信息学报(英文版)

CSTPCDCSCD
影响因子：0.495
ISSN：1672-0229
年,卷(期)：2023.21(5)
  • 102